Long-term hormonal therapy in intermediate-risk prostate cancer patients does not improve overall survival

A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. Men with advanced prostate cancer typically receive hormonal therapy to reduce the level of androgens, or male hormones, in their bodies...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news